Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Alchem solves...

    Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-16T16:47:30+05:30  |  Updated On 17 Aug 2021 12:44 PM IST

    Alchem's molecule is the sole micronized digoxin available globally that resolves the challenge of micro dosage formulation and the long-term stability and impurity issues with this specialist heart drug.


    New Delhi: Alchem International Private Limited ("Alchem"), a privately held pharmaceutical company focusing on the production of plant-derived active pharmaceutical ingredients (API); recently announced the launch of its proprietary micronized digoxin platform.


    Alchem's molecule is the sole micronized digoxin available globally that resolves the challenge of micro dosage formulation and the long-term stability and impurity issues with this specialist heart drug. Digoxin is commonly administered to treat various heart conditions including atrial fibrillation, atrial flutter, and heart failure.


    Micronization of digoxin, normally made for formulation homogeneity, dissolution and bioavailability, had previously led to an impractical and short shelf life (12 to 24 months) and the formation of impurities.


    Speaking from Alchem's European offices in Geneva (Switzerland) Raman Mehta, Alchem CEO and President, commented "Our process innovations mean that, for the first time since Boehringer Ingelheim announced in 2014 an end to production and supply of micronized digoxin to the market, drugmakers can be sure of supply and sure of the stability of this niche but important API. Raman Mehta continued "our customers are now able to formulate digoxin at the optimum particle size distribution (PSD) with a molecule that is stable for transport, stable for one-year storage at ambient temperatures (15 – 25 degrees Celsius) and stable for 4 years under cold storage (3 – 8 degrees Celsius).


    We fully expect the shelf life to be extended to 5 years in 2020 based on ongoing studies; our stability batches show Alchem manufactured digoxin to be stable with no change in the impurity profile and other properties either in long term stability or accelerated stability tests providing a clear advantage for handling and formulation".


    Alchem micronized digoxin EP, which has been developed by the company's R&D team using an inventive processing technique (patent filed), meets the strict EP monograph and is covered by European Certificate of Suitability (COS) issued by the European Directorate for the Quality of Medicines (EDQM).


    The state-of-the-art production site in Ballabgarh, India has been audited and approved by ANSM (French ministry of health) on behalf of EDQM.


    Expanding on the company's long-term production commitment and the challenge faced to overcome the stability issues, Raman Mehta provided more detail, "Alchem has been involved in the production and supply of digoxin for the past 20 years. We have invested heavily in manufacturing capabilities and a robust supply chain to ensure supply security for our customers, and we habitually hold safety stock to meet at least five year's demand."


    "The challenge we faced was to add a stable micronized digoxin molecule to our product portfolio that met the strict EDQM regulatory requirements on micronized APIs and was not cost prohibitive to manufacture. We had undertaken various experiments in the past with post-production micronizing but rejected this approach as this practice is no longer accepted by EDQM and produced an unstable molecule as well as a significant loss in manufacturing yields," Mehta added.


    "The novel process developed by our R&D team overcomes these barriers and achieves the optimum particle sized distribution (PSD) as part of the normal production method. This inventive production technique has enabled us to match the PSD of the originator product Lanoxin at near the same production costs as our standard (non-micronized) digoxin. As a result, our customers can achieve better tablet homogeneity and enhanced dissolution and bioavailability at close to the same cost as standard (non-micronized) digoxin," he further added.


    Also Read: Alchem International Launches Third Generation Phytomedicine to Combat Cough, Cold and Flu

    active pharmaceutical ingredientsAlchemAlchem InternationalAPIatrial fibrillationatrial flutterBoehringer IngelheimDigoxinEDQMEuropean Directorate for the Quality of Medicineshealth careheart drugheart failureLanoxinmicronized digoxinpharm anews indiapharmapharma newsPharmaceuticals

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok